Carl Ola Landgren, MD, PhD
1 clinical trials · Sponsor
◉ Watch Carl Ola Landgren, MD, PhD
| Record | Firm | Date |
|---|---|---|
| Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) (NCT06100237) | Carl Ola Landgren, MD, PhD | 2023-12-04 |
Track Carl Ola Landgren, MD, PhD automatically
Every clearance here is in the API, with alerts when new ones post.